1Schnitzler F, Fidder It, Ferrante M, et aLLong-term Out-come of Treatment with Infliximab in 614 Patientswith Crohn's Disease : Results from a Single-center Cohort[J], Gut, 2009, 58(4) : 492-500.
2Kraemer M, Kirschmeier A, Marth T.Perioperative Adjuvant Therapy with Infliximab in Complicated Anal Crohn' s Dis-ease[J].Int J Colorectal Dis, 2008, 23(10) : 965-969.
4De Ridder L, Rings E I4, Damen G M, et al. Infliximab De-pendency in Pediatric Crohn' s Disease : Longterm Follow-up of an Unselected Cohort[J].Inflamm Bowel Dis, 2008, 14(3) : 353-358.
4Breedveld FC. Tumour necrosis factor antagonists: Infliximab, adalimumab and etanercepr [J]: Nededands Tijdschriftvoor Genecskunde, 2005, 149(41):2273-2277.
5Clelland S, Hunek JR. Etanercept injection site reaction[J]. Dermatology Nursing, 2005,17(5):375.
6Haraoui B, Differentiating the efficacy of tumor necrosis factor inhibitors [J]. Journal of Rheumatology Supplement, 2005,74:3-7.
7Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis [J]. Annals of the Rheumatic Diseases,2002,61(9):850-851.
8Rita Bunikowski, Kerstin Gerhold,Matthias Brautigem, et al. Effect of low-dose cyclosporin A microemulsionon disease severity, interleukin-6, imerleukin-8 nd tumor necrosis factor alpha production in severe pediatric atopic dermatitis [J]. Internationl Archives of Allergy and Immunology,2001,125(4):344-348.
9Leonardo H Tonelli, Teodor T Postolache. Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge [J]. Neurlogical Research, 2005,27(7): 679-684.
